Skip to main content
Premium Trial:

Request an Annual Quote

BioReference Laboratories' Q4 Revenues Climb 18 Percent

NEW YORK (GenomeWeb) – BioReference Laboratories announced today that its fourth quarter revenues increased 18 percent year over year with the number of patients served jumping 9 percent.

The Elmwood Park, NJ-based clinical lab firm reported revenues of $227.6 million for its fiscal fourth quarter ended Oct. 31, up from $192.2 million for the fourth quarter of 2013.

The number of patients served grew to 2,550 in the quarter from 2,350 in Q4 2013, while revenue per patient increased 10 percent year over year to $88.67 from $80.80.

BRL posted net income of $18.3 million, or $.66 per share, for the quarter, compared to $11.1 million, or $.40 per share, for Q4 2013.

For FY 2014, BRL reported total revenues of $832.3 million, up 16 percent from $715.4 million in FY 2013. Its net income for the year was $46.8 million, or $1.68 per share, compared to $45.8 million, or $1.65 per share, for FY 2013.

BRL finished its fiscal year with $17.5 million in cash and cash equivalents.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.